BioCentury
ARTICLE | Clinical News

CHMP recommends Amgen's Avastin biosimilar ABP 215

November 17, 2017 3:33 AM UTC

EMA's CHMP recommended approval of ABP 215 from Amgen Inc. (NASDAQ:AMGN), a biosimilar of Avastin bevacizumab, for all cancer types on Avastin's EU label: non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal, breast, ovarian and cervical cancers.

Amgen said CHMP's recommendation is the committee's first for a biosimilar of Avastin...

BCIQ Company Profiles

Allergan plc

Amgen Inc.